Paratek Pharmaceuticals Inc. [NASDAQ: PRTK] price plunged by -9.45 percent to reach at -$0.85. The company report on June 14, 2021 that Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors.
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, announced the appointment of Minnie Baylor-Henry, J.D., a recognized leader in the area of food and drug laws and regulations, to the company’s Board of Directors.
“We’re delighted to welcome Minnie to Paratek’s Board of Directors,” said Michael Bigham, Chairman of the Board for Paratek. “She brings extensive expertise and unique perspectives from her work with top global businesses, government agencies and leading non-profit organizations that will be invaluable as we continue to pursue life cycle initiatives for NUZYRA and continue our commitment to supporting the fight against antimicrobial resistance.”.
A sum of 1285337 shares traded at recent session while its average daily volume was at 499.54K shares. Paratek Pharmaceuticals Inc. shares reached a high of $8.81 and dropped to a low of $8.135 until finishing in the latest session at $8.14.
The one-year PRTK stock forecast points to a potential upside of 55.76. The average equity rating for PRTK stock is currently 1.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Paratek Pharmaceuticals Inc. [PRTK]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PRTK shares is $18.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PRTK stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
WBB Securities have made an estimate for Paratek Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 23, 2021. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on March 02, 2021, representing the official price target for Paratek Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $19 to $22, while H.C. Wainwright kept a Buy rating on PRTK stock.
The Average True Range (ATR) for Paratek Pharmaceuticals Inc. is set at 0.65, with the Price to Sales ratio for PRTK stock in the period of the last 12 months amounting to 7.03.
PRTK Stock Performance Analysis:
Paratek Pharmaceuticals Inc. [PRTK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.53. With this latest performance, PRTK shares dropped by -1.69% in over the last four-week period, additionally plugging by 19.88% over the last 6 months – not to mention a rise of 77.73% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PRTK stock in for the last two-week period is set at 40.41, with the RSI for the last a single of trading hit 32.59, and the three-weeks RSI is set at 44.80 for Paratek Pharmaceuticals Inc. [PRTK]. The present Moving Average for the last 50 days of trading for this stock 8.35, while it was recorded at 9.70 for the last single week of trading, and 6.88 for the last 200 days.
Insight into Paratek Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Paratek Pharmaceuticals Inc. [PRTK] shares currently have an operating margin of -160.91 and a Gross Margin at +80.33. Paratek Pharmaceuticals Inc.’s Net Margin is presently recorded at -205.74.
Return on Total Capital for PRTK is now -40.30, given the latest momentum, and Return on Invested Capital for the company is -51.77. Additionally, PRTK Total Debt to Total Capital is recorded at 167.92, with Total Debt to Total Assets ending up at 142.56.
Reflecting on the efficiency of the workforce at the company, Paratek Pharmaceuticals Inc. [PRTK] managed to generate an average of -$490,056 per employee. Receivables Turnover for the company is 3.71 with a Total Asset Turnover recorded at a value of 0.22.Paratek Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.60 and a Current Ratio set at 6.20.
PRTK Stock EPS
With the latest financial reports released by the company, Paratek Pharmaceuticals Inc. posted -0.53/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -783.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRTK.
Paratek Pharmaceuticals Inc. [PRTK] Insider Position Details
There are presently around $197 million, or 54.90% of PRTK stock, in the hands of institutional investors. The top three institutional holders of PRTK stocks are: BLACKROCK INC. with ownership of 3,478,440, which is approximately 0.902% of the company’s market cap and around 6.40% of the total institutional ownership; OMEGA FUND MANAGEMENT, LLC, holding 2,600,410 shares of the stock with an approximate value of $21.17 million in PRTK stocks shares; and VANGUARD GROUP INC, currently with $17.86 million in PRTK stock with ownership of nearly -0.968% of the company’s market capitalization.
Positions in Paratek Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 35 institutional holders increased their position in Paratek Pharmaceuticals Inc. [NASDAQ:PRTK] by around 1,673,622 shares. Additionally, 50 investors decreased positions by around 1,359,249 shares, while 33 investors held positions by with 21,123,625 shares. The mentioned changes placed institutional holdings at 24,156,496 shares, according to the latest SEC report filing. PRTK stock had 8 new institutional investments in for a total of 219,246 shares, while 10 institutional investors sold positions of 393,422 shares during the same period.